<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169075</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0106/1510 SdS 01 QUALIOR</org_study_id>
    <nct_id>NCT03169075</nct_id>
  </id_info>
  <brief_title>QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program</brief_title>
  <acronym>QUALIOR</acronym>
  <official_title>Study Evaluating the Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program, for Metastatic Cancer Patients Receiving Oral Targeted Therapy: The UNICANCER SdS 01 QUALIOR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CAMI: Sport &amp; Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II-III study will randomize (2:1) patients starting first-line OTT for metastatic
      cancer between an individualized SPEP supervised by a personal coach, and recommended
      physical exercises via a booklet. Eligible patients will have received ≤2 lines of metastatic
      chemotherapy, ECOG PS ≤2, controlled pain (VAS &lt;3/10), and life expectancy ≥3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">March 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FACT-F relative on Fatigue</measure>
    <time_frame>Month 3 ( M3)</time_frame>
    <description>Self reported Questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FACT-G</measure>
    <time_frame>Month3 ( M3)</time_frame>
    <description>Self Reported Questionnaire relative on Well-Being Patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 75 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 75 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Month 1, Month 2, Month 3, and every 3 months for 1 year</time_frame>
    <description>Self reported Questionnaire on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Month 1, Month 2, Month 3, and every 3 months for 1 year</time_frame>
    <description>Self reported Questionnaire FACT-F on Fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Month 1, Month 2, Month 3, and every 3 months for 1 year</time_frame>
    <description>visual analogic scale for fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Month 1, Month 2, Month 3, and every 3 months for 1 year</time_frame>
    <description>visual analogic scale for pain (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities Secondaries effectsToxicities according NCI-CTC (National Cancer Institute Updates CTCAE to v.4.03. Common Terminology Criteria )</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3, and every 3 months for 1 year</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance about oral targeted therapy</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Self reported Questionnaire Morisky-Green</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit of physical activity: walk</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>6 minutes walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit of physical activity muscle function</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>muscle function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit of physical activity muscle strength</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>muscle strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity IPAQ</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>self reported Questionnaire IPAQ ( International Physical Activity Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity, Body Mass Index</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>Body Mass Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of anxiety and depression</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>Self reported questionnaire FACT-Cog</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Ingesta, Anorexia</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Ingesta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Ingesta, VAS</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Anorexia</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 and every 3 months for 1 year</time_frame>
    <description>Self reported FAACT (modul A-C)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Home Based Standardised Adapted Physical Activity Programme</condition>
  <condition>Patients Receiving Oraltargeted Therapy for Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A: A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B: B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PA</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SSPA</intervention_name>
    <description>A weekly supervised SPA session of 60 min at the patient's home is planned for 3 months.
These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalised and adapted to each patient's profile.
Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT modul AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE</description>
    <arm_group_label>ARM A: A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PA</intervention_name>
    <description>Program based on the recommendations for performing a physical activity A booklet containing physical activity recommendations will be given to the patients after randomisation.
The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.
Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT modul AC/S, FACT-Gog, HADS, IPAQ</description>
    <arm_group_label>ARM B: B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's ≥18 years old.

          2. Patient treated for a metastatic solid tumour within the following 4 cohorts: breast
             cancer, kidney cancer, lung cancer, and other tumours treated with oral targeted
             therapies (including melanomas, sarcomas, hepatic sarcomas, and colon cancers).

          3. Patients starting first-line oral targeted therapy, with market authorisation. The
             targeted therapy may be associated with hormonal therapy.

          4. Patients may have been treated with immunotherapy.

          5. Patients may have received chemotherapy (≤2 lines) for their metastatic disease.

          6. Life expectancy of ≥3 months.

          7. ECOG performance status ≥2.

          8. Patients able to comply with the constraints of the standardised supervised physical
             activity (SSPA) protocol.

          9. Pain under control (VAS ˂3; 0-10 scale).

         10. Haemoglobin level ≥9 g/dL.

         11. Patient must have signed the informed consent form before any study-related
             procedures.

         12. Patients must have public health insurance coverage.

        Exclusion Criteria:

          1. Patient receiving an injectable targeted therapy.

          2. Patient previously treated with an oral targeted therapy (previous cytokine treatment
             allowed).

          3. Patient to be treated with chemotherapy associated with the oral targeted therapy
             (hormonal therapy is allowed).

          4. Patient with known risk of fracture, symptomatic cardiac insufficiency (NYHA-3),
             respiratory insufficiency (grade 3), intense pain not controlled with analgesic
             treatment, and/or neuropathy (grade 3).

          5. Patients with a history of cancer in the last 5 years (except basal cell carcinoma
             adequately treated and in situ cervical cancer treated and cured).

          6. Patient treated with corticotherapy (˃1 month) before randomisation at a dose ˃1
             mg/kg.

          7. Bone metastases with risk of fractures.

          8. Geographical, sociological, or psychological reasons that could potentially hampering
             compliance with the study protocol and follow-up schedule.

          9. Patients with a history of non-compliance to medical treatment, reluctance or
             incapable to conform to the study protocol.

         10. Persons deprived of liberty or under guardianship. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence JOLY, MD PhD</last_name>
    <phone>+33 (0) 2 31 45 50 02</phone>
    <email>f.joly@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie PLENCE</last_name>
    <email>v-plence@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois - site d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74474</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laetitia Stefani, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Meneveau, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Joly, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Zenatti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHMG - Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>MD Phd</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire GARNIER-TIXIDRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique GIRRE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte Mastroianni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien SALAS, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO RenéGauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Nimes - Institut de Cancérologie du Gard</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadine HOUEDE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude BOIRON, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia LEFEUVRE-PLESSE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INSTITUT CURIE - Site René Huguenin St Cloud</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Boiron, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole Helissey, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adapted physical ctivity</keyword>
  <keyword>Oral targeted thérapy</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Randomized Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

